Resch I - Search Results

1

Treatment Patterns and Real-World Outcomes for Locally Advanced or Metastatic Urothelial Cancer in the Era of Immunotherapy.

Hassler MR, Moedlagl V, Hindinger H, Krauter J, Klager S, Resch I, Huebner N, Yurdakul O, Ofner H, Korn SM, D'Andrea D, Gust K, Shariat SF. Hassler MR, et al. Among authors: resch i. Eur Urol Focus. 2024 Sep;10(5):779-787. doi: 10.1016/j.euf.2023.12.005. Epub 2023 Dec 30. Eur Urol Focus. 2024. PMID: 38161107 Free article.

2

Anxiety and depression analyses of patients undergoing diagnostic cystoscopy.

Seklehner S, Engelhardt PF, Remzi M, Fajkovic H, Saratlija-Novakovic Z, Skopek M, Resch I, Duvnjak M, Hruby S, Wehrberger C, Librenjak D, Hübner W, Breinl E, Riedl C. Seklehner S, et al. Among authors: resch i. Qual Life Res. 2016 Sep;25(9):2307-14. doi: 10.1007/s11136-016-1264-z. Epub 2016 Mar 17. Qual Life Res. 2016. PMID: 26984467

3

Prospective, multi-institutional pain assessment of 150 women undergoing diagnostic cystoscopy.

Seklehner S, Saratlija-Novakovic Z, Skopek M, Fajkovic H, Remzi M, Duvnjak M, Resch I, Hruby S, lmHÜBNER W, Librenjak D, Breinl E, Riedl C, Engelhardt PF. Seklehner S, et al. Among authors: resch i. Minerva Urol Nefrol. 2016 Oct;68(5):417-23. Epub 2015 Sep 1. Minerva Urol Nefrol. 2016. PMID: 26329755

4

Biomarkers for immunotherapy in urological cancers.

Gust KM, Resch I, D'Andrea D. Gust KM, et al. Among authors: resch i. Curr Opin Urol. 2018 Jan;28(1):25-28. doi: 10.1097/MOU.0000000000000465. Curr Opin Urol. 2018. PMID: 29120910 Review.

5

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.

Soria F, Beleni AI, D'Andrea D, Resch I, Gust KM, Gontero P, Shariat SF. Soria F, et al. Among authors: resch i. World J Urol. 2018 Nov;36(11):1703-1709. doi: 10.1007/s00345-018-2264-0. Epub 2018 Mar 16. World J Urol. 2018. PMID: 29549485 Free PMC article.

6

PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer.

Resch I, Shariat SF, Gust KM. Resch I, et al. Memo. 2018;11(1):43-46. doi: 10.1007/s12254-018-0396-y. Epub 2018 Mar 8. Memo. 2018. PMID: 29606979 Free PMC article. Review.

7

Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer.

Stangl-Kremser; Mari A, D'Andrea D, Kimura S, Resch I, Shariat SF, Klatte T. Stangl-Kremser, et al. Among authors: resch i. Urol Int. 2018;101(2):197-200. doi: 10.1159/000489013. Epub 2018 Aug 8. Urol Int. 2018. PMID: 30089304

8

An update on systemic therapy for penile cancer.

Resch I, Abufaraj M, Hübner NA, Shariat SF. Resch I, et al. Curr Opin Urol. 2020 Mar;30(2):229-233. doi: 10.1097/MOU.0000000000000733. Curr Opin Urol. 2020. PMID: 31972637 Review.

9

Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer.

Gust KM, Rebhan K, Resch I, Shariat SF, Necchi A. Gust KM, et al. Among authors: resch i. Curr Opin Urol. 2020 Jul;30(4):547-556. doi: 10.1097/MOU.0000000000000783. Curr Opin Urol. 2020. PMID: 32453001 Review.

10

The role of taxane-based chemotherapy in the treatment of prostate cancer.

Huebner NA, Shariat SF, Resch I, Gust K, Kramer G. Huebner NA, et al. Among authors: resch i. Curr Opin Urol. 2020 Jul;30(4):527-533. doi: 10.1097/MOU.0000000000000784. Curr Opin Urol. 2020. PMID: 32453003 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters